Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab-Primed Immunotransplant for R/R DLBCL
NCT03305445Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- May 2018
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nivolumab and ipilimumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoints: Dose Limiting Toxicities at 3 months and Complete Remission Rate at 3 months. Started May 2018; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT03305445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03305445.